Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-9231 in intermediate-risk acute pulmonary embolism
NCT03316729Phase 2Withdrawn
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2018
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of TS23 in pulmonary embolism (PE), sponsored by Daiichi Sankyo Co., Ltd.. Planned start Jan 2018; status: withdrawn.
02
Drugs
TS23
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT03316729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03316729.